These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34875522)

  • 1. Design, synthesis, biochemical evaluation, radiolabeling and in vivo imaging with high affinity class-IIa histone deacetylase inhibitor for molecular imaging and targeted therapy.
    Turkman N; Liu D; Pirola I
    Eur J Med Chem; 2022 Jan; 228():114011. PubMed ID: 34875522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Contrast PET Imaging with [
    Turkman N; Xu S; Huang CH; Eyermann C; Salino J; Khan P
    J Med Chem; 2023 Apr; 66(8):5611-5621. PubMed ID: 37068265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and radiosynthesis of class-IIa HDAC inhibitor with high molar activity via repositioning the
    Xu S; Huang CH; Eyermann C; Georgakis GV; Turkman N
    Sci Rep; 2024 Jul; 14(1):15100. PubMed ID: 38956204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel late-stage radiosynthesis of 5-[18F]-trifluoromethyl-1,2,4-oxadiazole (TFMO) containing molecules for PET imaging.
    Turkman N; Liu D; Pirola I
    Sci Rep; 2021 May; 11(1):10668. PubMed ID: 34021207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.
    Lobera M; Madauss KP; Pohlhaus DT; Wright QG; Trocha M; Schmidt DR; Baloglu E; Trump RP; Head MS; Hofmann GA; Murray-Thompson M; Schwartz B; Chakravorty S; Wu Z; Mander PK; Kruidenier L; Reid RA; Burkhart W; Turunen BJ; Rong JX; Wagner C; Moyer MB; Wells C; Hong X; Moore JT; Williams JD; Soler D; Ghosh S; Nolan MA
    Nat Chem Biol; 2013 May; 9(5):319-25. PubMed ID: 23524983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
    Bürli RW; Luckhurst CA; Aziz O; Matthews KL; Yates D; Lyons KA; Beconi M; McAllister G; Breccia P; Stott AJ; Penrose SD; Wall M; Lamers M; Leonard P; Müller I; Richardson CM; Jarvis R; Stones L; Hughes S; Wishart G; Haughan AF; O'Connell C; Mead T; McNeil H; Vann J; Mangette J; Maillard M; Beaumont V; Munoz-Sanjuan I; Dominguez C
    J Med Chem; 2013 Dec; 56(24):9934-54. PubMed ID: 24261862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
    Luckhurst CA; Aziz O; Beaumont V; Bürli RW; Breccia P; Maillard MC; Haughan AF; Lamers M; Leonard P; Matthews KL; Raphy G; Stott AJ; Munoz-Sanjuan I; Thomas B; Wall M; Wishart G; Yates D; Dominguez C
    Bioorg Med Chem Lett; 2019 Jan; 29(1):83-88. PubMed ID: 30463802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain.
    Seo YJ; Muench L; Reid A; Chen J; Kang Y; Hooker JM; Volkow ND; Fowler JS; Kim SW
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6700-5. PubMed ID: 24210501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors.
    Muraglia E; Altamura S; Branca D; Cecchetti O; Ferrigno F; Orsale MV; Palumbi MC; Rowley M; Scarpelli R; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6083-7. PubMed ID: 18930398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [
    Laws MT; Bonomi RE; Kamal S; Gelovani DJ; Llaniguez J; Potukutchi S; Lu X; Mangner T; Gelovani JG
    Sci Rep; 2019 Mar; 9(1):3595. PubMed ID: 30837601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
    Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
    Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Class IIa Histone Deacetylases Expression and In Vivo Epigenetic Imaging in a Transgenic Mouse Model of Alzheimer's Disease.
    Chen YA; Lu CH; Ke CC; Chiu SJ; Chang CW; Yang BH; Gelovani JG; Liu RS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.
    Zeglis BM; Pillarsetty N; Divilov V; Blasberg RA; Lewis JS
    Nucl Med Biol; 2011 Jul; 38(5):683-96. PubMed ID: 21718944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity.
    Zwergel C; Di Bello E; Fioravanti R; Conte M; Nebbioso A; Mazzone R; Brosch G; Mercurio C; Varasi M; Altucci L; Valente S; Mai A
    ChemMedChem; 2021 Mar; 16(6):989-999. PubMed ID: 33220015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.
    Hsu KC; Liu CY; Lin TE; Hsieh JH; Sung TY; Tseng HJ; Yang JM; Huang WJ
    Sci Rep; 2017 Jun; 7(1):3228. PubMed ID: 28607401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers for PET Imaging of Epigenetic Regulation in the Brain.
    Bonomi R; Mukhopadhyay U; Shavrin A; Yeh HH; Majhi A; Dewage SW; Najjar A; Lu X; Cisneros GA; Tong WP; Alauddin MM; Liu RS; Mangner TJ; Turkman N; Gelovani JG
    PLoS One; 2015; 10(8):e0133512. PubMed ID: 26244761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide.
    Canzoneri JC; Chen PC; Oyelere AK
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6588-90. PubMed ID: 19854643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity.
    Ibrahim TS; Sheha TA; Abo-Dya NE; AlAwadh MA; Alhakamy NA; Abdel-Samii ZK; Panda SS; Abuo-Rahma GEA; Mohamed MFA
    Bioorg Chem; 2020 Jun; 99():103797. PubMed ID: 32247939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors.
    Narita K; Matsuhara K; Itoh J; Akiyama Y; Dan S; Yamori T; Ito A; Yoshida M; Katoh T
    Eur J Med Chem; 2016 Oct; 121():592-609. PubMed ID: 27318982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.